TG Therapeutics/TGTX

$16.49

-1.32%
-
1D1W1MYTD1YMAX

About TG Therapeutics

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Ticker

TGTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Weiss

Employees

284

Headquarters

Morrisville, United States

TG Therapeutics Metrics

BasicAdvanced
$2.6B
Market cap
75.79
P/E ratio
$0.22
EPS
2.31
Beta
-
Dividend rate
$2.6B
2.3065
$29.32
$6.46
3.7M
3.617
2.838
63.286
63.286
59.802
4.01%
14.44%
43.93%
20.2%
75.786
8.925
16.131
16.21
127.325
3,275.73%
117.91%
1,054.11%

What the Analysts think about TG Therapeutics

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 6 analysts.
87.99% upside
High $49.00
Low $7.00
$16.49
Current price
$31.00
Average price target

TG Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-16.87% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$63M
44.42%
Net income
-$11M
-25.69%
Profit margin
-16.87%
-48.57%

TG Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 96%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.34
$0.73
-$0.10
-$0.07
-
Expected
-$0.25
$0.12
-$0.10
-$0.04
-$0.05
Surprise
36.68%
530.87%
-4.11%
96%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for TG Therapeutics stock?

TG Therapeutics (TGTX) has a market cap of $2.6B as of May 28, 2024.

What is the P/E ratio for TG Therapeutics stock?

The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 75.79 as of May 28, 2024.

Does TG Therapeutics stock pay dividends?

No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next TG Therapeutics dividend payment date?

TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.

What is the beta indicator for TG Therapeutics?

TG Therapeutics (TGTX) has a beta rating of 2.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the TG Therapeutics stock price target?

The target price for TG Therapeutics (TGTX) stock is $31, which is 87.99% above the current price of $16.49. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell TG Therapeutics stock

Buy or sell TG Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing